F. Hoffmann-La Roche Ltd: Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Roche's Kadcyla is the first targeted therapy to show globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Greatest benefit continued to be seen in people who are at a high risk of recurrence (those with lymph node-positive disease)With longer follow-up, treatment effect continues to be seen regardless of hormone
Health Canada approves Perjeta for use pre-surgery in patients with aggressive early breast cancer[1] newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.